Docetaxel News and Research

RSS
Docetaxel is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of breast and non-small cell lung cancer (NSCLC). It is also approved to be used with other drugs to treat squamous cell carcinoma of the head and neck (SCCHN) and certain types of gastric and prostate cancer.

Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent.
Combination of three technologies makes potential treatment effective against aggressive brain tumor

Combination of three technologies makes potential treatment effective against aggressive brain tumor

NSCLC patients treated with KRAS G12C inhibitor sotorasib may receive long-term clinical benefit

NSCLC patients treated with KRAS G12C inhibitor sotorasib may receive long-term clinical benefit

Novel radioligand therapy shown to increase survival of metastatic prostate cancer patients

Novel radioligand therapy shown to increase survival of metastatic prostate cancer patients

New combination treatment strategy for managing metastatic hormone-sensitive prostate cancer

New combination treatment strategy for managing metastatic hormone-sensitive prostate cancer

Combination of three drugs extends the survival of patients with metastatic, hormone-sensitive prostate cancer

Combination of three drugs extends the survival of patients with metastatic, hormone-sensitive prostate cancer

Regular blood tests can identify prostate cancer patients who are resistant to treatment

Regular blood tests can identify prostate cancer patients who are resistant to treatment

Advancements in the diagnosis and treatment of prostate cancer are saving more lives

Advancements in the diagnosis and treatment of prostate cancer are saving more lives

New drug shows promise against lung cancer caused by genetic mutation

New drug shows promise against lung cancer caused by genetic mutation

New drug reduces tumor size in lung cancer patients who have a specific, disease-causing change

New drug reduces tumor size in lung cancer patients who have a specific, disease-causing change

Study examines impact of chemotherapy on mechanical properties of prostate cancer cells

Study examines impact of chemotherapy on mechanical properties of prostate cancer cells

Study: One in six men with advanced prostate cancer experiences reduced sense of smell and taste

Study: One in six men with advanced prostate cancer experiences reduced sense of smell and taste

Scientists test the effect of natural product isolated from sea sponge on cancer cells

Scientists test the effect of natural product isolated from sea sponge on cancer cells

Phase III study of (m)RNA expression did not confer significant advantage for stage II-III lung cancer

Phase III study of (m)RNA expression did not confer significant advantage for stage II-III lung cancer

New nanomedicine is efficient and less aggressive than conventional prostate cancer therapy

New nanomedicine is efficient and less aggressive than conventional prostate cancer therapy

Common chemotherapy drug may be less effective in overweight, obese breast cancer patients

Common chemotherapy drug may be less effective in overweight, obese breast cancer patients

Scientists develop a lead compound to fight chemotherapy-resistant prostate cancer

Scientists develop a lead compound to fight chemotherapy-resistant prostate cancer

AI could enhance prediction of treatment response among patients with non-small cell lung cancer

AI could enhance prediction of treatment response among patients with non-small cell lung cancer

AI may help predict tumor sensitivity to systemic cancer therapies

AI may help predict tumor sensitivity to systemic cancer therapies

Global study shows long-term survival benefit for a subset of patients with advanced lung cancer

Global study shows long-term survival benefit for a subset of patients with advanced lung cancer

Novel inhibitor to fight metastatic prostate cancer shows promise

Novel inhibitor to fight metastatic prostate cancer shows promise